Cleveland BioLabs is at the bottom of the weekly box

Despite reporting $1.9 million net loss for the second quarter of 2016 technical analysis stipulates the shares of the company would at least double its value.
The point is that there was a bullish engulfing at the bottom of a significant rectangle which lasts more than a year. Moreover RSI(5) analysis implies divergence which coupled with double bottom increases the chances a winning trade.
For more ideas visit mercurius.wordpress.com